Oscar Health, Inc. (NYSE: OSCR), a technology-driven health insurer focused on the individual ACA marketplace, has been one of the strongest healthcare stocks of the past year. After trading near $10 in late 2025, the stock has more than tripled, recently changing hands around $30. The question on many investors' minds is whether the rally can extend to the psychologically significant $40 stock price target—a level just above both the stock's 52-week high and the highest analyst price target on Wall Street.
Oscar Health has delivered a dramatic operational turnaround. In the first quarter of 2026, the company reported a record profit of roughly $679 million, driven by membership growth of more than 50% and lower medical costs. Revenue climbed 52.7% year over year to approximately $4.65 billion, while earnings per share of $2.07 far exceeded consensus estimates. The key metric for health insurers—the medical loss ratio, which measures the share of premiums spent on claims—improved to about 70.5%, a level that signals strong profitability.
The company has followed this momentum with continued beats, including a second quarter where EPS of $1.10 surpassed the $0.40 consensus and revenue rose 70.4% year over year. This execution has pushed shares to a market capitalization of roughly $9 billion and a trailing price-to-earnings (P/E) ratio near 23.
Several factors support the case for continued upside. Membership growth of more than 50% indicates Oscar Health is taking meaningful share in the individual ACA market, with particular concentration in high-growth states such as Florida, Texas, and Georgia. The company's proprietary "+Oscar" technology platform provides a differentiated, lower-cost operating model relative to traditional insurers.
On the valuation front, some analysts argue the stock still looks inexpensive. Barclays analyst Andrew Mok, who raised his target to $39 with an "Overweight" rating, noted the company offers "single-line exposure" to the fast-growing ACA marketplace while trading at a fraction of the multiple assigned to comparable insurers. A narrowing of that valuation gap would be a direct catalyst for the stock to approach $40.
Wall Street's view is improving but remains cautious. The consensus rating is a "Hold," with an average price target near $30—roughly in line with the current price. Targets range widely, from a low of $16 to a high of $39, the latter set by Barclays. Piper Sandler holds a $36 target, while Wells Fargo, UBS, and Baird cluster in the $26–$27 range.
The fact that even the most bullish analyst target sits just below $40 underscores both the ambition and the risk of that level. For the stock to reach $40, the market would need to price Oscar Health above the most optimistic Street forecast—typically requiring continued earnings beats and upward estimate revisions.
The most visible headwind is insider selling. In recent months, insiders have sold more than $100 million worth of stock, including substantial sales by CEO Mark Bertolini and other executives, largely under pre-arranged trading plans. While the CEO also purchased one million shares near $12 in April 2026, the overall pattern of selling has raised questions about how much upside management sees at current levels.
Policy risk is another concern. Oscar Health's business is heavily concentrated in the ACA individual marketplace, which depends on government subsidies. Any change to subsidy structures or pricing regulations could pressure enrollment and profitability. Analysts have repeatedly flagged "subsidy expiration risk" and uncertainty around the second-half medical loss ratio as factors that could compress margins.
From a technical analysis standpoint, the immediate hurdle is the 52-week high near $33.55. A decisive, high-volume break above that level would establish a new range and clear the path toward the $35–$36 zone, where Piper Sandler's and Stephens' targets sit. Above that, $39–$40 becomes the next major resistance level, effectively representing both the highest analyst target and a round-number psychological barrier.
On the downside, the $27–$30 area—where several recent analyst targets and the stock's 50-day moving average reside—serves as a key support level. Holding above this zone would keep the broader uptrend intact, while a breakdown could signal that the rally has exhausted itself.
Traders tracking Oscar Health and thousands of other equities can use Tickeron's AI Daily Buy/Sell Signals to monitor shifting conditions. The product uses artificial intelligence to continuously scan stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market behavior, technical patterns, and AI-driven analysis. These signals can help investors identify emerging opportunities, manage existing positions, and spot evolving trends more efficiently than manual screening alone.
A move to $40 for Oscar Health is ambitious but not out of reach. The company's turnaround is real: record profits, surging membership, and a strong medical loss ratio have fundamentally re-rated the stock from its 2025 lows. If earnings continue to beat expectations and the valuation gap with peers narrows, a break above the 52-week high toward the $39–$40 zone is plausible.
However, the path is not guaranteed. Insider selling, policy dependence on ACA subsidies, and a consensus analyst target still near $30 all suggest the stock is currently pricing in significant optimism. Investors should watch for sustained trading above the $33.55 high, continued membership growth, and whether the medical loss ratio remains favorable through the seasonally weaker second half of the year. As always, price targets represent possibilities rather than promises, and no level should be treated as a certainty.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, OSCR has been loosely correlated with CNC. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if OSCR jumps, then CNC could also see price increases.
| Ticker / NAME | Correlation To OSCR | 1D Price Change % | ||
|---|---|---|---|---|
| OSCR | 100% | +0.58% | ||
| CNC - OSCR | 46% Loosely correlated | +1.56% | ||
| ELV - OSCR | 38% Loosely correlated | +0.52% | ||
| HUM - OSCR | 38% Loosely correlated | +2.26% | ||
| UNH - OSCR | 35% Loosely correlated | -2.37% | ||
| MOH - OSCR | 33% Poorly correlated | +1.97% | ||
More | ||||